EYPT
Price
$9.70
Change
-$0.13 (-1.32%)
Updated
Aug 1, 04:59 PM (EDT)
Capitalization
667.13M
5 days until earnings call
VYNE
Price
$0.35
Change
-$0.02 (-5.41%)
Updated
Aug 1, 04:59 PM (EDT)
Capitalization
5.88M
Interact to see
Advertisement

EYPT vs VYNE

Header iconEYPT vs VYNE Comparison
Open Charts EYPT vs VYNEBanner chart's image
EyePoint Pharmaceuticals
Price$9.70
Change-$0.13 (-1.32%)
Volume$7.04K
Capitalization667.13M
VYNE Therapeutics
Price$0.35
Change-$0.02 (-5.41%)
Volume$100
Capitalization5.88M
EYPT vs VYNE Comparison Chart in %
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. VYNE commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and VYNE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (EYPT: $9.83 vs. VYNE: $0.37)
Brand notoriety: EYPT and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 63% vs. VYNE: 352%
Market capitalization -- EYPT: $667.13M vs. VYNE: $5.88M
EYPT [@Biotechnology] is valued at $667.13M. VYNE’s [@Biotechnology] market capitalization is $5.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileVYNE’s FA Score has 2 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • VYNE’s FA Score: 2 green, 3 red.
According to our system of comparison, EYPT is a better buy in the long-term than VYNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 4 TA indicator(s) are bullish while VYNE’s TA Score has 4 bullish TA indicator(s).

  • EYPT’s TA Score: 4 bullish, 4 bearish.
  • VYNE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than VYNE.

Price Growth

EYPT (@Biotechnology) experienced а -6.29% price change this week, while VYNE (@Biotechnology) price change was -72.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +16.82%, and the average quarterly price growth was +37.20%.

Reported Earning Dates

EYPT is expected to report earnings on Oct 29, 2025.

VYNE is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($667M) has a higher market cap than VYNE($5.88M). EYPT YTD gains are higher at: 31.946 vs. VYNE (-89.087). VYNE has higher annual earnings (EBITDA): -45.44M vs. EYPT (-144.55M). EYPT has more cash in the bank: 318M vs. VYNE (50.3M). VYNE has less debt than EYPT: VYNE (63K) vs EYPT (24.1M). EYPT has higher revenues than VYNE: EYPT (56M) vs VYNE (605K).
EYPTVYNEEYPT / VYNE
Capitalization667M5.88M11,342%
EBITDA-144.55M-45.44M318%
Gain YTD31.946-89.087-36%
P/E RatioN/A0.71-
Revenue56M605K9,256%
Total Cash318M50.3M632%
Total Debt24.1M63K38,254%
FUNDAMENTALS RATINGS
EYPT vs VYNE: Fundamental Ratings
EYPT
VYNE
OUTLOOK RATING
1..100
7652
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
4298
P/E GROWTH RATING
1..100
161
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYNE's Valuation (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for EYPT (59). This means that VYNE’s stock grew somewhat faster than EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (88) in the Pharmaceuticals Major industry is in the same range as VYNE (100). This means that EYPT’s stock grew similarly to VYNE’s over the last 12 months.

EYPT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as VYNE (97). This means that EYPT’s stock grew similarly to VYNE’s over the last 12 months.

EYPT's Price Growth Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for VYNE (98). This means that EYPT’s stock grew somewhat faster than VYNE’s over the last 12 months.

VYNE's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as EYPT (16). This means that VYNE’s stock grew similarly to EYPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTVYNE
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 15 days ago
86%
Bullish Trend 24 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BON1.370.05
+3.79%
Bon Natural Life Limited
ODD69.990.50
+0.72%
ODDITY Tech Ltd
HVT20.63-0.24
-1.15%
Haverty Furniture Companies
KEQU55.34-0.81
-1.44%
Kewaunee Scientific Corp
SQM36.75-0.62
-1.66%
Sociedad Quimica y Minera de Chile SA